Day: July 28, 2020

Copperstone recruits merited Site Manager for Viscaria Copper Project

Written by Customer Service on July 28, 2020. Posted in Public Companies.

Danderyd, July 28th, 2020Copperstone Resources AB (publ) recruits merited Anna Tyni as Site Manager for the Viscaria-project in Kiruna, Sweden. Anna Tyni has 20 years of experience from a number of leading positions within LKAB, primarily in enrichment, production and logistics. As Site Manager she will have staff liability for the team in Kiruna as well as overall responsibility for the preparations for the reopening of the Viscaria mine.”We are very pleased that Anna Tyni has accepted this important role in the Viscaria project. She has shown drive and commitment in the recruitment process and combined with her experience and local knowledge, I am convinced that she will play a central role in the important steps we see ahead of us before the reopening of the mine. With strong recent test drilling results and the latest key recruitments,...

Copperstone rekryterar meriterad Site Manager för Viscaria kopparprojekt

Written by Customer Service on July 28, 2020. Posted in Public Companies.

Danderyd den 28 juli 2020Copperstone Resources AB (publ) rekryterar meriterade Anna Tyni som Site Manager för Viscaria-projektet i Kiruna. Anna Tyni har 20-årig erfarenhet från en rad ledande positioner inom LKAB, framför allt inom anrikning, produktion och logistik. Som Site Manager kommer hon att ha personalansvar för teamet i Kiruna samt det övergripande ansvaret för förberedelserna inför återöppningen av Viscaria-gruvan.”Vi är väldigt glada att Anna Tyni tackat ja till denna viktiga roll i Viscaria-projektet. Hon har i rekryteringsprocessen visat ett tydligt driv och engagemang och kombinerat med hennes erfarenheter och lokalkännedom är jag övertygad om att hon kommer ha en central roll i de viktiga steg vi ser framför oss inför återöppningen av gruvan. Med starka färska provborrningsresultat och de senaste nyckelrekryteringarna har...

STMicroelectronics Announces Reallocation of Shares Repurchased under its Share Buy-back Program

Written by Customer Service on July 28, 2020. Posted in Public Companies.

STMicroelectronics Announces Reallocation ofShares Repurchased under its Share Buy-back ProgramGeneva, Switzerland, July 28, 2020 – STMicroelectronics (NYSE: STM) (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announced on November 5, 2018 the launch of a share buy-back program of up to $750 million to be executed within a 3 year period (subject to shareholder and other approvals from time to time) (the “Programme”). The Company announces today that it will utilize a certain number of shares (the “Settlement Treasury Shares”), repurchased under the Programme for delivery of shares in connection with the early redemption of its outstanding US$750 million Zero Coupon Convertible Bonds due 2022 (ISIN: XS1638064953, the “2022 Convertible Bonds”) pursuant...

STMicroelectronics annonce la réaffectation des actions rachetées dans le cadre de son programme de rachat d’actions

Written by Customer Service on July 28, 2020. Posted in Public Companies.

STMicroelectronics annonce la réaffectation des actions rachetées dans le cadre de son programme de rachat d’actionsGenève, Suisse, le 28 juillet 2020 – STMicroelectronics (NYSE: STM) (la “Société” ou “STMicroelectronics”), un leader mondial des semiconducteurs dont les clients couvrent toute la gamme des applications électroniques, a annoncé le 5 novembre 2018, le lancement d’un programme de rachat d’actions pour un montant maximal de 750 millions de dollars, sur une période de 3 ans (sous réserve de l’approbation de l’assemblée des actionnaires et d’autres autorisations éventuelles) (le “Programme”). La Société annonce aujourd’hui qu’une partie des actions rachetées dans le cadre du Programme (les “Actions Auto Détenues pour Livraison”) seront utilisées pour la remise d’actions dans le cadre du remboursement anticipé des Obligations...

DOVRE GROUP’S HALF-YEAR FINANCIAL REPORT 1.1.–30.6.2020: Net sales increased by 13% and profitability improved in January–June 2020

Written by Customer Service on July 28, 2020. Posted in Earnings Releases And Operating Results.

Dovre Group Plc Half year financial statement July 28, 2020 at 8.45 a.m.DOVRE GROUP’S HALF-YEAR FINANCIAL REPORT 1.1.–30.6.2020: Net sales increased by 13% and profitability improved in January–June 2020The figures presented in this half-year financial report are not audited. Last year’s corresponding period in parentheses.January–June 2020Net sales grew by 13.0% to EUR 43.2 (38.2) millionProject Personnel: net sales totaled EUR 35.5 (35.2) million – increase of 0.8%.Consulting: net sales totaled EUR 7.7 (3.0) million – increase of 155.9%.Operating result improved to EUR 1.2 (0.6) million.Profit before tax was EUR 1.2 (0.4) million including EUR 0.1 (-0.1) million of finance items.Result for the period improved to EUR 1.1 (0.2) million.Earnings per share EUR 0.011 (0.002).Net cash...

DOVRE GROUPIN PUOLIVUOSIKATSAUS 1.1.–30.6.2020: Liikevaihto kasvoi 13 % ja kannattavuus parani tammi–kesäkuussa 2020

Written by Customer Service on July 28, 2020. Posted in Earnings Releases And Operating Results.

Dovre Group Oyj Puolivuosikatsaus 28.7.2020 klo 8.45DOVRE GROUPIN PUOLIVUOSIKATSAUS 1.1.–30.6.2020: Liikevaihto kasvoi 13 % ja kannattavuus parani tammi–kesäkuussa 2020Tämän liiketoimintakatsauksen luvut ovat tilintarkastamattomia. Suluissa edellisvuoden vastaavan ajankohdan vertailuluvut.Tammi–kesäkuu 2020Liikevaihto kasvoi 13 prosenttia 43,2 milj. euroon (38,2 milj. euroa)Projektihenkilöstö: liikevaihto 35,5 (35,2) milj. euroa – kasvua 0,8 %Konsultointi: liikevaihto 7,7 (3,0) milj. euroa – kasvua 155,9 %Liiketulos nousi 1,2 milj. euroon (0,6 milj. euroa) – kasvua 109,7 %Tulos ennen veroja oli 1,2 (0,4) milj. euroa, joka sisältää 0,1 (-0,1) milj. euroa rahoituseriä.Kauden tulos parani 1,1 (0,2) milj. euroon – kasvua 407,1%.Osakekohtainen tulos 0,011 (0,002) euroa.Liiketoiminnan...

Innofactor Oyj:n puolivuosikatsaus 1.1.–30.6.2020 (IFRS)

Written by Customer Service on July 28, 2020. Posted in Earnings Releases And Operating Results.

Innofactor Oyj:n puolivuosikatsaus 28.7.2020 klo 9.00 Innofactorin liikevaihto kasvoi Q2:lla ja H1:lla ja käyttökatteessa saavutettiin Innofactorin historialliset ennätykset vertailukausiin nähden

Innofactor Plc’s Half-Yearly Report for January 1–June 30, 2020 (IFRS)

Written by Customer Service on July 28, 2020. Posted in Earnings Releases And Operating Results.

Innofactor Plc Half-Yearly Report July 28, 2020, at 9:00 Finnish time Innofactor’s net sales grew on Q2 and H1, and the operating margin reached record highs as regards the comparison periods

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

Written by Customer Service on July 28, 2020. Posted in Public Companies.

HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review status to the New Drug Application (“NDA”) for savolitinib for the treatment of non-small cell lung cancer (“NSCLC”) with MET Exon 14 skipping mutations. This is the first NDA filing for savolitinib globally and first for a selective MET inhibitor in China.With over 774,000 new cases every year, China accounted for 37% of the world’s annual incidence of lung cancer in 2018.1 Approximately 80-85% of lung cancer cases are NSCLC.2 It is estimated that 2-3% of NSCLC patients have MET Exon 14 skipping mutations; these mutations lead to poor prognosis.3 The annual incidence of MET Exon 14 skipping...

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Written by Customer Service on July 28, 2020. Posted in Public Companies.

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly. The 2020 Amendment covers the expansion of Chi-Med’s role in the commercialization of Elunate® (fruquintinib capsules) in China.Under the terms of the 2020 Amendment, Lilly will maintain the exclusive commercialization rights, and as a consequence, will continue to consolidate the sales of Elunate® in China. Chi-Med will collaborate with Lilly in commercializing Elunate® across China.In a joint statement, Mr. Christian Hogg, CEO of Chi-Med and Mr. Julio Gay-Ger, President & General Manager, Lilly China, said “After...

Day: July 28, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals